Aerosolized antibiotics in the treatment of hospital-acquired pneumonia/ventilator-associated pneumonia

키워드

참고문헌 (73)

1. Klompas M, "Multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation", PLoS One, 6, pp.e18062~ (2011)
2. Bor C, "Ventilator-associated pneumonia in critically ill patients with intensive antibiotic usage", Pak J Med Sci, 31, pp.1441~1446 (2015)
3. Kalil AC, "Management of adults with hospital-acquired and ventilator-associated pneumonia : 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clin Infect Dis, 63, pp.e61~e111 (2016)
4. Schreiber MP, "Challenges and opportunities in the treatment of ventilator-associated pneumonia", Expert Rev Anti Infect Ther, 15, pp.23~32 (2017)
5. Micek ST, "An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia : impact of multidrug resistance", Crit Care, 19, pp.219~ (2015)
6. Garnacho-Montero J, "Acinetobacter baumannii ventilator-associated pneumonia : epidemiological and clinical findings", Intensive Care Med, 31, pp.649~655 (2005)
7. Tacconelli E, "Discovery, research, and development of new antibiotics : the WHO priority list of antibiotic-resistant bacteria and tuberculosis", Lancet Infect Dis, 18, pp.318~327 (2018)
8. 김은진, "전국의료관련감염감시체계 중환자실 부문 결과 보고: 2018년 7월부터 2019년 6월", 의료관련감염관리, 25(2), pp.115~127 (2020), 대한의료관련감염관리학회[DOI]
9. Imberti R, "Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration", Chest, 138, pp.1333~1339 (2010)
10. Roberts JA, "DALI : defining antibiotic levels in intensive care unit patients : are current β-lactam antibiotic doses sufficient for critically ill patients?", Clin Infect Dis, 58, pp.1072~1083 (2014)
11. Luyt CE, "Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia : an update", Expert Rev Anti Infect Ther, 11, pp.511~521 (2013)
12. Kuhn RJ, "Formulation of aerosolized therapeutics", Chest, 120(3 Suppl), pp.94~ (2001)[DOI]
13. "Approved drug products with therapeutic equivalence evaluations" (2020)[URL]
14. Swenson C, "Amikacin liposome inhalation suspension as a treatment option for refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex", Mayo Clin Proc, 95, pp.201~202 (2020)
15. Heijerman H, "Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis : a European consensus", J Cyst Fibros, 8, pp.295~315 (2009)
16. Beckhouse MJ, "Altered aminoglycoside pharmacokinetics in the critically ill", Anaesth Intensive Care, 16, pp.418~422 (1988)
17. Triginer C, "Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation", Eur J Clin Pharmacol, 40, pp.297~302 (1991)
18. Roberts JA, "Pharmacokinetic issues for antibiotics in the critically ill patient", Crit Care Med, 37, pp.840~851 (2009)
19. Dhanani JA, "Lung pharmacokinetics of tobramycin by intravenous and nebulized dosing in a mechanically ventilated healthy ovine model", Anesthesiology, 131, pp.344~355 (2019)
20. Ehrmann S, "Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects", Intensive Care Med, 34, pp.755~762 (2008)
21. Rouby JJ, "Aerosolized antibiotics for ventilator-associated pneumonia : lessons from experimental studies", Anesthesiology, 117, pp.1364~1380 (2012)
22. Goldstein I, "Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets", Am J Respir Crit Care Med, 166, pp.1375~1381 (2002)
23. Luyt CE, "Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin(NKTR-061)in intubated and mechanically ventilated patients with nosocomial pneumonia", Crit Care, 13, pp.R200~ (2009)
24. Niederman MS, "BAY41-6551 Achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia", Intensive Care Med, 38, pp.263~271 (2012)
25. Ioannidou E, "Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia : a meta-analysis", J Antimicrob Chemother, 60, pp.1216~1226 (2007)
26. Sole-Lleonart C, "Nebulization of antiinfective agents in invasively mechanically ventilated adults : a systematic review and meta-analysis", Anesthesiology, 126, pp.890~908 (2017)
27. Hassan NA, "Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries : a randomized controlled trial", Crit Care Med, 46, pp.45~52 (2018)
28. Kollef MH, "A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia : IASIS trial", Chest, 151, pp.1239~1246 (2017)
29. Niederman MS, "Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia(INHALE) : a double-blind, randomised, placebo-controlled, phase 3, superiority trial", Lancet Infect Dis, 20, pp.330~340 (2020)
30. Ari A, "Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation", Respir Care, 55, pp.845~851 (2010)
31. Harvey CJ, "Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation", Eur Respir J, 10, pp.905~909 (1997)
32. Ferrari F, "Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets : ultrasonic versus vibrating plate nebulizers", Intensive Care Med, 34, pp.1718~1723 (2008)
33. Miller DD, "Aerosol delivery and modern mechanical ventilation : in vitro", in vivo evaluation, 2003, pp.168, 1205~1209
34. Michotte JB, "In vitro comparison of a vibrating mesh nebulizer operating in inspiratory synchronized and continuous nebulization modes during noninvasive ventilation", J Aerosol Med Pulm Drug Deliv, 29, pp.328~336 (2016)
35. Vardakas KZ, "Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis : a systematic review and meta-analysis", Int J Antimicrob Agents, 51, pp.1~9 (2018)
36. Lu Q, "Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa", Intensive Care Med, 36, pp.1147~1155 (2010)
37. Gontijo AV, "Biopharmaceutical characterization of nebulized antimicrobial agents in rats : 2. Colistin", Antimicrob Agents Chemother, 58, pp.3950~3956 (2014)
38. Kwa AL, "Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa", Clin Infect Dis, 41, pp.754~757 (2005)
39. Naesens R, "A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa", BMC Infect Dis, 11, pp.317~ (2011)
40. Lin CC, "Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia : experience in a tertiary care hospital in northern Taiwan", J Microbiol Immunol Infect, 43, pp.323~331 (2010)
41. Athanassa ZE, "Pharmacokinetics of inhaled colistimethate sodium(CMS)in mechanically ventilated critically ill patients", Intensive Care Med, 38, pp.1779~1786 (2012)
42. Boisson M, "Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate(CMS)and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients", Antimicrob Agents Chemother, 58, pp.7331~7339 (2014)
43. Rattanaumpawan P, "Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria", J Antimicrob Chemother, 65, pp.2645~2649 (2010)
44. Abdellatif S, "Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia : a prospective, randomised trial", Ann Intensive Care, 6, pp.26~ (2016)
45. Valachis A, "The role of aerosolized colistin in the treatment of ventilator-associated pneumonia : a systematic review and metaanalysis", Crit Care Med, 43, pp.527~533 (2015)
46. Falagas ME, "Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia : a meta-analysis of comparative trials", Crit Care, 10, pp.R123~ (2006)
47. Karvouniaris M, "Nebulised colistin for ventilator-associated pneumonia prevention", Eur Respir J, 46, pp.1732~1739 (2015)
48. Povoa FCC, "Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia : a systematic review and meta-analysis", J Crit Care, 43, pp.240~245 (2018)
49. Torres A, "International ERS", ESICM, ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia : Guidelines for the management of hospital-acquired pneumonia(HAP), pp.ventilator-associated pneumonia(VAP)of the European Respiratory Society(ERS), European Society of Intensive Care Medicine(ESICM), European Society of Clinical Microbiology and Infectious Diseases(ESCMID)and Asociacion Latinoamericana del Torax(ALAT), Eur Respir J[DOI]
50. Rello J, "Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults : a position paper from the European Society of Clinical Microbiology and Infectious Diseases", Clin Microbiol Infect, 23, pp.629~639 (2017)
51. 박성주, "Clinical Effectiveness and Nephrotoxicity of Aerosolized Colistin Treatment in Multidrug-Resistant Gram-Negative Pneumonia", Acute and Critical Care, 31(3), pp.208~220 (2016), 대한중환자의학회
52. Min KL, "Risk factors of colistin safety according to administration routes : Intravenous and aerosolized colistin", PLoS One, 13, pp.e0207588~ (2018)
53. Kim YK, "Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii", J Thorac Dis, 9, pp.555~567 (2017)
54. Choe J, "Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria", Ther Adv Respir Dis, 13, pp.1753466619885529~ (2019)
55. Kahler DA, "Toxic serum trough concentrations after administration of nebulized tobramycin", Pharmacotherapy, 23, pp.543~545 (2003)
56. Petitcollin A, "Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients", J Antimicrob Chemother, 71, pp.3482~3486 (2016)
57. Lu Q, "Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa", Am J Respir Crit Care Med, 184, pp.106~115 (2011)
58. Barker AF, "Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis", Am J Respir Crit Care Med, 162(2 Pt 1), pp.481~485 (2000)
59. Polverino E, "European Respiratory Society guidelines for the management of adult bronchiectasis", Eur Respir J, 50, pp.1700629~ (2017)
60. Demers RR, "Bacterial", viral filtration: let the breather beware!, 2001, pp.120, 1377~1389
61. Palmer LB, "Aerosolized antibiotics in mechanically ventilated patients : delivery and response", Crit Care Med, 26, pp.31~39 (1998)
62. Davies JB, "Bacterial filter obstruction with the use of ultrasonic nebulisation", Anaesthesia, 66, pp.394~395 (2011)
63. Lucato JJ, "Evaluation of resistance in 8 different heat-and-moisture exchangers : effects of saturation and flow rate", profile, 2005, pp.50, 636~643
64. van Doremalen N, "van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARSCoV-1", N Engl J Med, 382, pp.1564~1567 (2020)
65. "GINA report: global strategy for asthma management and prevention (updated 2021)" (2021)[URL]
66. Ari A, "Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19", Respir Med, 167, pp.105987~ (2020)
67. Reychler G, "Nebulization : a potential source of SARS-CoV-2 transmission", Respir Med Res, 78, pp.100778~ (2020)
68. Alanis AJ, "Resistance to antibiotics : are we in the post-antibiotic era?", Arch Med Res, 36, pp.697~705 (2005)
69. Spellberg B, "The epidemic of antibiotic-resistant infections : a call to action for the medical community from the Infectious Diseases Society of America", Clin Infect Dis, 46, pp.155~164 (2008)
70. Vincent JL, "International study of the prevalence and outcomes of infection in intensive care units", JAMA, 302, pp.2323~2329 (2009)
71. Palmer LB, "Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit", Am J Respir Crit Care Med, 189, pp.1225~1233 (2014)
72. Ramsey BW, "Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", N Engl J Med, 340, pp.23~30 (1999)
73. Moss RB, "Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis", Chest, 121, pp.55~63 (2002)

관련 논문AI추천